Last reviewed · How we verify
Transdermal Oestradiol
At a glance
| Generic name | Transdermal Oestradiol |
|---|---|
| Also known as | Progynova TS |
| Sponsor | Medical Research Council |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- Estradiol Supplementation and Rotator Cuff Repair (PHASE2)
- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial (PHASE2)
- COMPASS - COpenhagen MenoPAuSe Study (PHASE2)
- Intrauterine Stent Placement Following Hysteroscopic Septum Resection (NA)
- Impact of Estradiol on Endothelial Function in Peri-Menopausal Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transdermal Oestradiol CI brief — competitive landscape report
- Transdermal Oestradiol updates RSS · CI watch RSS
- Medical Research Council portfolio CI